Vivos’ DNA appliance shows promise for children with sleep apnea

LITTLETON, Colo. - A new clinical trial published in the European Journal of Pediatrics has demonstrated that the Vivos DNA appliance is both safe and effective for treating obstructive sleep apnea (OSA) in children, Vivos Therapeutics, Inc. (NASDAQ:VVOS) announced Wednesday. The medical device company, currently valued at $25.52 million with annual revenues of $14.39 million, has maintained a healthy gross profit margin of 55.91% despite recent market challenges. According to InvestingPro analysis, the stock appears undervalued based on its Fair Value metrics.

The multicenter study found that 77% of pediatric participants experienced at least a 50% reduction in OSA severity when using the Daytime-Nighttime Appliance, which is part of the company’s Complete Airway Repositioning and Expansion (C.A.R.E.) line of devices.

Among children with severe OSA, 93% reached a 50% reduction in severity, while 17% of all patients achieved complete resolution of their condition. The study also reported an average 67.8% increase in airway volume.

According to research estimates cited in the press release, up to 20.4% of U.S. children may have pediatric OSA, with approximately 90% remaining undiagnosed. The current standard treatment is adenotonsillectomy surgery, which the company notes is only effective for 20-40% of pediatric patients.

"For over a century, surgery has been the go-to treatment for children with OSA," said Kirk Huntsman, Chairman and CEO of Vivos Therapeutics. "With these results, parents and providers now have strong evidence supporting our DNA appliance as a safe, non-surgical alternative." While the clinical results are promising, InvestingPro data shows the stock has experienced significant volatility, dropping 10.76% in the past week. Subscribers can access 8 additional ProTips and comprehensive financial analysis through the Pro Research Report.

The company also offers Vivos Guides, specialized devices designed for guided jaw growth and development in children, which may help prevent the need for OSA treatment later in life.

Vivos Therapeutics’ devices have received FDA clearance for adult patients with all severity levels of OSA and for moderate-to-severe OSA in children ages 6 to 17.

The information in this article is based on a company press release statement.

In other recent news, Vivos Therapeutics reported its second-quarter 2025 earnings, which did not meet analyst expectations. The company announced a loss per share of $0.55, missing the forecasted loss of $0.39 by 41.03%. Despite this, Vivos Therapeutics managed to slightly exceed revenue expectations, reporting $3.8 million compared to the anticipated $3.78 million. These earnings results are significant for investors as they reflect the company’s current financial performance. No mergers or acquisitions were reported in the recent updates. Additionally, there were no analyst upgrades or downgrades mentioned in the recent reports. These developments are crucial for investors to consider when evaluating Vivos Therapeutics.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.